BRPI0508540B8 - composto, composição farmacêutica, e, uso de um composto - Google Patents

composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0508540B8
BRPI0508540B8 BRPI0508540A BRPI0508540A BRPI0508540B8 BR PI0508540 B8 BRPI0508540 B8 BR PI0508540B8 BR PI0508540 A BRPI0508540 A BR PI0508540A BR PI0508540 A BRPI0508540 A BR PI0508540A BR PI0508540 B8 BRPI0508540 B8 BR PI0508540B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
compounds
pharmaceutical compositions
concerns
Prior art date
Application number
BRPI0508540A
Other languages
English (en)
Inventor
Fecher Anja
Fretz Heinz
Hilpert Kurt
Riederer Markus
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508540(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0508540A publication Critical patent/BRPI0508540A/pt
Publication of BRPI0508540A8 publication Critical patent/BRPI0508540A8/pt
Publication of BRPI0508540B1 publication Critical patent/BRPI0508540B1/pt
Publication of BRPI0508540B8 publication Critical patent/BRPI0508540B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

composto, composição farmacêutica, e, uso de um composto a invenção diz respeito a derivados de tetraidropiridoindol e a seu uso como ingredientes ativos na preparação de composições farmacêuticas. a invenção também diz respeito a aspectos relacionados que incluem processos para a preparação dos compostos, composições farmacêuticas que compreendem um ou mais daqueles compostos e métodos de tratamento que compreende a administração dos ditos compostos.
BRPI0508540A 2004-03-11 2005-03-07 composto, composição farmacêutica, e, uso de um composto BRPI0508540B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2004002493 2004-03-11
EPPCT/EP2004/002493 2004-03-11
PCT/EP2005/002362 WO2005095397A1 (en) 2004-03-11 2005-03-07 Tetrahydropyridoindole derivatives

Publications (4)

Publication Number Publication Date
BRPI0508540A BRPI0508540A (pt) 2007-09-18
BRPI0508540A8 BRPI0508540A8 (pt) 2017-12-26
BRPI0508540B1 BRPI0508540B1 (pt) 2019-04-02
BRPI0508540B8 true BRPI0508540B8 (pt) 2021-05-25

Family

ID=34961211

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508540A BRPI0508540B8 (pt) 2004-03-11 2005-03-07 composto, composição farmacêutica, e, uso de um composto

Country Status (24)

Country Link
US (2) US7714132B2 (pt)
EP (1) EP1725553B1 (pt)
JP (1) JP4051398B2 (pt)
KR (1) KR100808742B1 (pt)
CN (1) CN1930162B (pt)
AR (1) AR047928A1 (pt)
AT (1) ATE394399T1 (pt)
AU (1) AU2005229356B2 (pt)
BR (1) BRPI0508540B8 (pt)
CA (1) CA2558509C (pt)
DE (1) DE602005006539D1 (pt)
DK (1) DK1725553T3 (pt)
ES (1) ES2304010T3 (pt)
IL (1) IL177968A0 (pt)
MY (1) MY143795A (pt)
NO (1) NO337996B1 (pt)
NZ (1) NZ550365A (pt)
PL (1) PL1725553T3 (pt)
PT (1) PT1725553E (pt)
RU (1) RU2387652C2 (pt)
SI (1) SI1725553T1 (pt)
TW (1) TWI369356B (pt)
WO (1) WO2005095397A1 (pt)
ZA (1) ZA200608446B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594280C (en) 2004-12-27 2013-04-23 Anja Fecher 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
PT2037967T (pt) 2006-06-16 2017-03-14 Univ Pennsylvania Antagonistas do recetor de prostaglandina d2 para o tratamento da alopecia androgenética
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
EP2316824A1 (en) * 2006-08-07 2011-05-04 Actelion Pharmaceuticals Ltd. (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates
EP2099444A4 (en) 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
CA2679866A1 (en) 2007-03-09 2008-09-18 High Point Pharmaceuticals, Llc Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors
RU2338745C1 (ru) * 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2009049021A1 (en) * 2007-10-10 2009-04-16 Chemietek, Llc Heterocyclic compounds as crth2 receptor antagonists
HK1150388A1 (en) * 2008-01-25 2011-12-23 Medivation Technologies Inc New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof 2345--1h-[43-b]
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
EP2300425A4 (en) * 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
PT2401269E (pt) * 2009-02-24 2014-03-11 Merck Canada Inc Derivados de indol como antagonistas de recetor crth2
SG177736A1 (en) * 2009-07-31 2012-02-28 Panmira Pharmaceuticals Llc Dermal formulations of dp2 receptor antagonists
WO2011117798A1 (en) * 2010-03-22 2011-09-29 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
KR101928595B1 (ko) 2011-04-14 2018-12-12 이도르시아 파마슈티컬스 리미티드 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도［1,2-ａ］인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절자로서의 이의 용도
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
ES2654161T3 (es) * 2013-05-28 2018-02-12 Astrazeneca Ab Compuestos químicos
LT3119779T (lt) 2014-03-17 2018-09-10 Idorsia Pharmaceuticals Ltd Azaindolo acto rūgšties dariniai ir jų panaudojimas kaip prostaglandino d2 receptoriaus moduliatorių
US9850241B2 (en) 2014-03-18 2017-12-26 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
EP3328500B1 (en) 2015-07-30 2023-04-12 The Trustees of the University of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 antagonists
JP6833852B2 (ja) 2015-09-15 2021-02-24 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 結晶形
AU2019232153B2 (en) * 2018-03-09 2023-07-13 Panoptes Pharma Ges.M.B.H. Ophthalmic formulation
SI3810283T1 (sl) 2018-06-21 2023-10-30 F. Hoffmann-La Roche Ag Trdne oblike tartratne soli 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido(3,4-b)indol-2-il)-2,2- difluoropropan-1-ola, postopek za njihovo pripravo in metode njihove uporabe pri zdravljenju raka
KR20210008223A (ko) 2019-07-11 2021-01-21 제이투에이치바이오텍 (주) 탈모증의 치료 또는 개선을 위한 화합물 및 이들의 용도

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
CA2171446C (en) 1993-09-09 2004-11-23 Donald James Kyle Pseudo- and non-peptide bradykinin receptor antagonists
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
ATE337294T1 (de) 1995-06-21 2006-09-15 Shionogi & Co Bizyklische aminoderivate und enthaltende pgd2- antagonisten
RU2140417C1 (ru) * 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
ATE295360T1 (de) 1996-12-12 2005-05-15 Shionogi & Co Kondensierte heterocyclische benzolcarbonsäureamid-derivate und diese enthaltende pgd2 antagonisten
IL130660A (en) 1996-12-13 2002-03-10 Shionogi & Co History of benzothiophenecarboxamide and PGD2 antibodies containing them
DE69925270T2 (de) 1998-06-03 2006-02-23 Shionogi & Co., Ltd. Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
CA2383135C (en) 1999-08-23 2010-11-30 Hiroyuki Hirai Method of identifying properties of substance with respect to human prostaglandin d2 receptors
CA2405233A1 (en) 2000-04-12 2001-10-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
WO2001094309A1 (fr) 2000-06-02 2001-12-13 Shionogi & Co., Ltd. Composition medicamenteuse antagoniste pour les recepteurs de pgd2/txa2
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
DE60108515T2 (de) 2000-10-17 2006-01-12 Shionogi & Co., Ltd. Verfahren zur herstellung eines pgd2-antagonisten
EP1338594A4 (en) 2000-11-01 2004-06-16 Shionogi & Co PGD2 RECEPTOR ANTAGONIST PHARMACEUTICAL COMPOSITIONS
FR2821854B1 (fr) 2001-03-09 2004-07-16 Genoway Cellules et animaux transgeniques d'etude de la polarisation de la reponse immune
US7144913B2 (en) 2001-05-23 2006-12-05 Merck Frosst Canada & Co. Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
US20040185509A1 (en) 2001-07-18 2004-09-23 Francois Gervais Eosinophil prostaglandin d2 receptor assays
US20040197834A1 (en) 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1505061A4 (en) * 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
JPWO2003097042A1 (ja) 2002-05-16 2005-09-15 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗剤
GB2388540A (en) * 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
JP2006511486A (ja) 2002-10-21 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｃｒｔｈ２拮抗剤としてのテトラヒドロキノリン誘導体
US7618979B2 (en) 2002-10-30 2009-11-17 Merck Frosst Canada Ltd. Pyridopyrrolizine and pyridoindolizine derivatives
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
EP1435356A1 (en) 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
WO2004074240A1 (ja) 2003-02-20 2004-09-02 Taisho Pharmaceutical Co. Ltd. プロスタグランジン誘導体
US20060089353A1 (en) 2003-03-06 2006-04-27 Maki Iwahashi Indole derivative compounds and drugs containing the compounds as the active ingredient
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
AU2004240705A1 (en) 2003-05-20 2004-12-02 Merck Frosst Canada & Co. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
CA2527773A1 (en) 2003-06-12 2004-12-23 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines as dp receptor antagonists
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
CA2558545C (en) 2004-03-11 2012-10-16 Actelion Pharmaceuticals Ltd Indol-1-yl-acetic acid derivatives
US8273740B2 (en) 2004-08-26 2012-09-25 Actelion Pharmaceuticals, Ltd. 2-sulfanyl-benzoimidazol-1-yi-acetic acid derivatives as CRTH2 antagonists
CA2594280C (en) 2004-12-27 2013-04-23 Anja Fecher 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
EP2316824A1 (en) 2006-08-07 2011-05-04 Actelion Pharmaceuticals Ltd. (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates

Also Published As

Publication number Publication date
DE602005006539D1 (de) 2008-06-19
DK1725553T3 (da) 2008-08-18
US20070191416A1 (en) 2007-08-16
AU2005229356A1 (en) 2005-10-13
EP1725553B1 (en) 2008-05-07
ES2304010T3 (es) 2008-09-01
PT1725553E (pt) 2008-07-16
ZA200608446B (en) 2008-06-25
WO2005095397A1 (en) 2005-10-13
KR100808742B1 (ko) 2008-02-29
RU2006135651A (ru) 2008-04-20
AR047928A1 (es) 2006-03-01
MY143795A (en) 2011-07-15
US20100234396A1 (en) 2010-09-16
NO337996B1 (no) 2016-07-18
CN1930162A (zh) 2007-03-14
JP2007526276A (ja) 2007-09-13
TW200538434A (en) 2005-12-01
US7714132B2 (en) 2010-05-11
CN1930162B (zh) 2010-06-16
IL177968A0 (en) 2006-12-31
ATE394399T1 (de) 2008-05-15
CA2558509C (en) 2011-11-22
BRPI0508540A8 (pt) 2017-12-26
NO20064584L (no) 2006-10-10
BRPI0508540B1 (pt) 2019-04-02
EP1725553A1 (en) 2006-11-29
CA2558509A1 (en) 2005-10-13
TWI369356B (en) 2012-08-01
BRPI0508540A (pt) 2007-09-18
KR20070029670A (ko) 2007-03-14
SI1725553T1 (sl) 2008-08-31
PL1725553T3 (pl) 2008-10-31
NZ550365A (en) 2010-09-30
AU2005229356B2 (en) 2011-06-09
RU2387652C2 (ru) 2010-04-27
JP4051398B2 (ja) 2008-02-20

Similar Documents

Publication Publication Date Title
BRPI0508540B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
NO20082269L (no) Nye piperaziner som antimalariamidler
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
NO20075111L (no) Farmasoytisk sammensetning
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
UY28271A1 (es) Compuestos químicos
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0414777A (pt) compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
BRPI0409882A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0614197B8 (pt) composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0519921A2 (pt) composto enanciopuro ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica,e, uso de composto quìmico ou de um sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2661 DE 04-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.